
In order to ensure the sustainability of the existence, activities and business continuity of our company, which produces pharmaceuticals destined to national and international markets for local and multinational companies, to reach its strategic, operational and financial goals and to protect its reputation, in line with TS ISO 31000 Risk Management, we commit to:
- Proactively evaluate possible opportunities and threats through risk assessments realized for all business processes in order to manage them within a predetermined framework of risk levels and to reach strategic goals, to base all decision-making mechanisms on risk management,
- Produce high quality and safe products in accordance with standards by employees having high awareness levels, appropriate education and training, and to treat risks that will endanger the quality, efficacy, reliability of the product and patient health as unacceptable risks,
- Sustain preventive measures in line with continuous technological improvement,
- Ensuring customer satisfaction and continuity within the scope of current Good Manufacturing Practices (cGMP), standard operating procedures and agreements by considering people and human health as a priority, by accepting compliance with the regulations as a bare minimum and keeping the sense of quality and the protective approach to the environment above commercial targets,
- Monitoring the performance of the processes within the framework of risk management and allocating the necessary resources in order to manage the risks,
- Manage the risks with the participation and support of all employees and to continuously improve the effectiveness of our management system,
- Sharing our Risk Management Policy with all our stakeholders and reviewing it regularly.
Dr. Ünsal Hekiman
Chief Executive Officer/General Manager